Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

• Main Authors: Diansong Zhou (Author), Terry Podoll (Author), Yan Xu (Author), Ganesh Moorthy (Author), Karthick Vishwanathan (Author), Joseph Ware (Author), J. Greg Slatter (Author), Nidal Al‐Huniti (Author)
• Format: Book
• Published: Wiley, 2019-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 to predict potential drug-drug interactions (DDIs). The...